Risk factors of linezolid-related thrombocytopenia in patients in the department of hepatobiliary surgery
10.12206/j.issn.2097-2024.202210061
- VernacularTitle:肝胆外科肿瘤患者应用利奈唑胺致血小板减少危险因素分析
- Author:
Xuechun SHAN
1
;
Xu LI
1
;
Hongli DU
1
;
Leilei BAO
1
;
Hui WANG
1
Author Information
1. Department of Pharmacy, Third Affiliated Hospital of Naval Medical University, Shanghai, 200438, China.
- Keywords:
hepatobiliary surgery;
cancer patients;
linezolid;
thrombocytopenia;
risk factors
- From:
Journal of Pharmaceutical Practice
2023;41(11):694-699
- CountryChina
- Language:Chinese
-
Abstract:
Objective To provide the evidence for clinical medication safety by the investigation of the risk factors of linezolid-related thrombocytopenia in cancer patients in the department of hepatobiliary surgery. Methods Patients who received linezolid for anti-infective treatment from January 2017 to December 2021 were selected. The patients were divided into thrombocytopenia group and non-thrombocytopenia group according to whether thrombocytopenia occurred or not after administration of linezolid. The general data and laboratory indicators of the two groups were compared, and the risk factors of linezolid-related thrombocytopenia were screened by multivariate logistic regression analysis. Results A total of 104 patients were included in the study, including 84 patients who underwent surgery and 20 patients who did not. The incidence of linezolid-related thrombocytopenia was 24.0%. There were significant differences in gender, age, duration of linezolid use, platelet count, white blood cell count, alanine aminotransferase(ALT), aspartate aminotransferase(AST), total bilirubin, creatinine, estimated glomerular filtration rate between the two groups (P<0.05); logistic regression analysis suggested that age ≥60 years (OR=7.093; P=0.017), duration of linezolid use ≥12 days (OR=4.399; P=0.035), baseline platelet count ≤200×109/L (OR=8.470; P=0.004), baseline AST≥50 U/L (OR=15.465; P<0.001), and baseline white blood cell count ≥11×109/L (OR=11.436; P=0.001) were the risk factors for linezolid-related thrombocytopenia in cancer patients. Conclusion During the treatment of linezolid in cancer patients, attention should be paid to the adverse reactions of thrombocytopenia in the patients, especially those with old age, long-term treatment, low baseline platelets, poor baseline liver function, and high baseline white blood cell counts.
